DPP-4 inhibitor
Linagliptin
LINAGLIPTIN
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 54.65) | 0.56 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.60 (0.01 to 46.03) | 0.59 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.63 (0.01 to 49.15) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.25 (0.00 to 7.50) | 0.84 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.33 (0.01 to 9.96) | 0.74 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.72 (0.01 to 62.01) | 0.56 |